Condition: Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · Sponsor: Blueprint Medicines Corporation
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Allervie Clinical Research | Birmingham, Alabama, United States | — |
| Acuro Research, Inc. | Little Rock, Arkansas, United States | — |
| Modena Allergy & Asthma Clinical Research - La Jolla | La Jolla, California, United States | — |
| Allergy & Asthma Associates of Southern California | Laguna Niguel, California, United States | — |
| Allergy & Asthma Medical Group and Research Center | San Diego, California, United States | — |
| Allergy Affiliates Inc. | Bradenton, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Treasure Valley Medical Research | Boise, Idaho, United States | — |
| Endeavor Health | Northbrook, Illinois, United States | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, Indiana, United States | — |
| Southern Indiana Clinical Trials | New Albany, Indiana, United States | — |
| The Indiana Clinical Trials Center | Plainfield, Indiana, United States | — |
+ 35 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.